About Tirzepatide Script — An Independent Editorial Digest

About Tirzepatide Script

Tirzepatide Script is an independent editorial project that publishes summaries of the peer-reviewed research literature on Tirzepatide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site name carries the word "script" as editorial framing — a position relative to the literature, not a claim about services. Tirzepatide Script does not prescribe, does not dispense, does not refer, and does not advise. There is no medical professional behind the publication. There is no storefront.

What the name signals is intent: a careful, annotated reading of the dual-incretin record — the mechanism studies, the phase 3 trial programmes, the safety literature, the cardiovascular and metabolic outcomes data — organised for readers who want to understand what the studies actually measured rather than receive a recommendation.

This is an FDA-approved compound with a substantial clinical trial record. The literature is publicly available and consequential. Tirzepatide Script summarises it plainly, cites it completely, and takes no position on what any individual should do with the information.

Editorial standards

Every quantitative claim on this site is cited to a numbered reference in the references list. Citation numbers appear inline as [N] in the body text. The references list includes DOIs and PubMed URLs for all primary literature.

We do not invent research. If a finding is not documented in the cited literature, it does not appear on this site. We do not use competitor brand names. We use the international nonproprietary name (INN) "tirzepatide" throughout.

The site is updated periodically as the literature develops. It does not carry real-time updates and does not substitute for consulting the most current FDA prescribing information, which remains the authoritative document for clinical use.

Comments, corrections, and source suggestions are welcome via the contact page.

The beta-cell and insulin sensitivity lens

This site's particular editorial emphasis — the angle from which the tirzepatide literature is presented — is the beta-cell function and insulin sensitivity dimension of the compound's pharmacology. That emphasis reflects the disposition-index evidence from the Heise 2022 Lancet Diabetes Endocrinol mechanistic trial and the subsequent SURPASS-1, SURPASS J-mono, and SURMOUNT-1 post-hoc analyses that collectively make the strongest case for why dual GIP/GLP-1 agonism outperforms selective GLP-1 agonism: not only larger weight and HbA1c reductions, but a measurably greater improvement in the functional capacity of the glucose-regulatory system.

For the weight and HbA1c evidence alone, the SURMOUNT and SURPASS programmes speak clearly. The beta-cell and insulin sensitivity story adds the mechanistic dimension: a plausible explanation, grounded in pharmacology and corroborated in clinical mechanistic studies, for why the numbers are what they are.